Parenteral preparations injections

Parenteral preparations injection solutions, infusion solutions... 

Water for injection (WFI) is the most widely used solvent for parenteral preparations. The USP requirements for WFI and purified water have been recently updated to replace the traditional wet and colorimetric analytical methods with the more modern and cost-effective methods of conductivity and total organic carbon. Water for injection must be prepared and stored in a manner to ensure purity and freedom from pyrogens. The most common means of obtaining WFI is by the distillation of deionized water. This is the only method of preparation permitted by the European Pharmacopoeia (EP). In contrast, the USP and the Japanese Pharmacopeias also permit reverse osmosis to be used. The USP has also recently broadened its definition of source water to include not only the U.S. Environmental Protection Agency National Primary Drinking Water Standards, but also comparable regulations of the European Union or Japan. 

Irritation. Tissue irritation upon injection, and the accompanying damage and pain, is a concern that must be addressed for the final formulation, which is to be either tested in humans or marketed, rather than for the active ingredient. This is because most irritation factors are either due to or influenced by aspects of formulation design (see Avis, 1985, for more information or parenteral preparations). These factors are not independent of the route (TV, IM, or SC) that will be used and, in fact (as discussed later), are part of the basis for selecting between the various routes. 

Age or body weight can affect the systemic availability of many antimicrobial agents. In the physically smaller animal (sheep and pig) the peak serum concentration of a drug is usually higher and is followed by a rapid decline compared with a lower peak and a slower decline of the antibiotic in seruon of the larger animal (cow and horse). The limited experimental data appear to indicate that the extent of systemic availability of IM-administored antibiotics can vary as widely between different sites as between IM and SC sites. A corollary to this observation is that the location of the extra-vascular injection site should be well-defined when determining the systemic availability of parenteral preparations (9). 

Parenteral use Inject IM preparations deep into musculature properly dilute IV preparations and administer over an appropriate time interval. 

Speed of haemopoietic response is not quicker than that with full doses of oral iron reliably taken and normally absorbed, for both provide as much iron as an active marrow can use, but a course of injected iron is stored and utilised over months. The ionised salts of iron given orally are unsuitable as parenteral preparations as they are powerful protein precipitants and un-ionised iron complexes are used. 

The use of cosolvents in small-volume parenteral preparations is often critical due to the limited volume of solution that can be administered by a single injection. Thus, the required dose of drug must often be incorporated in 1 or 2mL of solution. Table 6 lists parenteral products containing cosolvents. The cosolvents most often used include ethanol, propylene glycol, glycerin, PEG 400, and, sometimes, dimethylacetamide. Other cosolvents, such as DMSO, have been used as solvents for parenteral formulations of experimental anticancer agents however, their use is restricted due to toxicity and potential incompatibilities with plastic administration devices. ... 

The type of dosage form, the route of administration, and site of injection of parenteral preparations depend on the animal species or group of related species (such as ruminant animals or poultry). The greatest differences relate to oral dosage forms and topical preparations. Whether a veterinary dosage form is intended for individual animal treatment or for... 

The plasma concentration profiles can vary widely among different parenteral preparations of the same drug administered by intramuscular injection, even when the same injection site is used. Comparison of the plasma concentration profiles obtained after intramuscular injection in the lateral neck of ruminant calves of five different parenteral preparations of ampi-cillin at a similar dose level (7.7 l.Omg/kg) serves to illustrate the variation that can exist among preparations (Fig. 5). Estimation of the bioavailability of each preparation relative to a reference preparation... 

Almond oil is used therapeutically as an emollient and to soften ear wax. As a pharmaceutical excipient it is employed as a vehicle in parenteral preparations, such as oily phenol injection. It is also used in nasal spray,and topical preparations. Almond oil is also consumed as a food substance, see Section 18. 

Chlorocresol is used primarily as a preservative in topical pharmaceutical formulations but has also been used in nebulized solutions and ophthalmic and parenteral preparations. It should not, however, be used in formulations for intrathecal, intracisternal, or peridural injection. 

The use of dimethyl sulfoxide to improve transdermal delivery has been reported for ciclosporin, timolol, and a wide range of other drugs.Dimethyl sulfoxide has also been used in the formulation of an injection containing allopur-inol. It has also been investigated for use in an experimental parenteral preparation for the treatment of liver tumors. ... 

Included in the FDA Inactive Ingredients Guide (IM and SC injections, oral capsules, emulsions, and tablets, also topical preparations). Included in parenteral (IM injections) and nonparenteral (oral capsules and sprays) medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. 

Inject volumes of <1 ml, using water-soluble parenteral preparations. 

Repeated injections cause significant local trauma and injections cannot be continued indefinitely. Some drug formulations are not suitable for subconjunctival injection (e.g. parenteral preparations of NSAIDs). 

Subconjunctival antibiotic injections will result in local tissue necrosis and clinicians must use their discretion in assessing the therapeutic benefits against continued treatment. Water-soluble parenteral preparations should be used the recommended doses of antibiotics for subconjunctival injection are shown in Table 13.1. 

In another study carried out in fasted ponies, the oral administration of a flunixin meglumine paste (l.lmg/kg) resulted in peak plasma concentrations >2 jLg/ml less than 1 h after administration (Welsh et al 1992). In ponies with free access to hay, the peak plasma concentration decreased to approximately 1.3 j,g/ml and the peak concentration was not reached until 7.6 h after administration (Welsh et al 1992). Nevertheless, the mean area under the plasma concentration-time curve (AUC) was not significantly different whether the ponies had been fasted or fed. The parenteral preparation of flunixin meglumine can be administered i.m. however, necrotizing soft-tissue infections have been reported following i.m. administration (Kahn Styrt 1997) and so aseptic preparation of the injection site is advisable. 

Drug absorption from an intramuscular injection site is mainly determined by the formulation of the parenteral preparation and is influenced by the... 

The extent of absorption (systemic availability) of a drug is estimated by the method of corresponding areas. Comparison of total AUC following the intramuscular injection of a parenteral preparation (solution or suspension) with that following the intravenous injection of a bolus dose of the drug (parenteral solution) provides an estimation of absolute bioavailability, while comparison of AUCs following intramuscular injection of different parenteral preparations (one of which must be a reference formulation) at the same injection site or of the same parenteral preparation at different injection sites estimates the relative bioavailability. A crossover design with an appropriate washout period between the phases of the bioavailability study should be used whenever feasible. 

---